

Navigating Treatment Options

For Patients With HR+/HER2- Advanced Breast Cancer



Friday, 2 December 2022 | 12:45–14:15 SGT
Summit 2, Level 3, Suntec Singapore Convention & Exhibition Centre, Singapore



Richard Hendry de Boer, MBBS, FRACP
 Consultant Medical Oncologist
 Peter MacCallum Cancer Centre and
 the Epworth-Freemasons Hospital
 Melbourne, Australia



Yen-Shen Lu, MD, PhD
 Division Chief and Professor of Medical Oncology
 Department of Oncology
 National Taiwan University Hospital
 Taipei, Taiwan



Soo Chin Lee, MBBS, FRCP
 Medical Oncologist and Professor
 National University Cancer Institute
 Singapore

Meeting objectives:

- Review recent evidence from CDK4/6 inhibitor trials that may impact treatment decisions in patients with HR+/HER2- advanced breast cancer
- Discuss second-line treatment options for patients with HR+/HER2- advanced breast cancer who progress on a first-line CDK4/6 inhibitor
- Provide expert insights on relevant patient populations and treatment outcomes for these patients

Agenda:

- Welcome and Introduction
- Survival Outcomes With First-Line CDK4/6i for Patients With HR+/HER2- Advanced Breast Cancer
- Second-Line Treatment Options for Patients With HR+/HER2- Advanced Breast Cancer
- Roundtable Discussion
- Key Takeaways and Live Q&A

This scientific information may include data information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program and/or materials were developed for use outside of the US, intended for non-US are HCPs, and are to be used in accordance with local laws and regulations.